Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.75 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | FRK | P42685 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.43 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890124 | 0.86 | MAPK14 (1.00) | MAPK14PTGS2 | |
| SCHEMBL3887574 | 0.85 | MAPK14 (0.83) | MAPK14PTGS2 | |
| SCHEMBL4258899 | 0.85 | MAPK14 (0.75) | MAPK14PTGS2 | |
| SCHEMBL29593759 | 0.84 | MAPK14 (1.00) | MAPK14PTGS2IKBKBMAPK13PRKD3 | |
| SCHEMBL4265458 | 0.84 | MAPK14 (1.00) | MAPK14PTGS2IKBKBMAPK13PRKD3 | |
| SCHEMBL3898491 | 0.83 | MAPK14 (0.73) | MAPK14PTGS2 | |
| SCHEMBL6280887 | 0.83 | MAPK14 (1.00) | MAPK14PTGS2 | |
| SCHEMBL4261017 | 0.83 | MAPK14 (0.72) | MAPK14PTGS2 | |
| SCHEMBL4266052 | 0.82 | MAPK14 (1.00) | MAPK14IKBKBMAPK13PRKD3MAP4K4 | |
| SCHEMBL4268190 | 0.82 | MAPK14 (1.00) | MAPK14PTGS2IKBKBMAPK13PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048307-A1 | 5-pyridyl-1, 3-azole compounds, process for producing the same and use there of | OHKAWA SHIGENORI | 2009-02-19 | — | — | US | disclosed |
| US-7276527-B2 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-02 | — | — | US | disclosed |
| EP-1180518-B1 | 5-PYRIDYL-1,3-AZOLE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-7101899-B1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-05 | — | — | US | disclosed |
| US-20060135566-A1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | OHKAWA SHIGENORI | 2006-06-22 | — | — | US | disclosed |
| WO-2006006691-A2 | SOLID DISPERSION OF A P38 MAP KINASE INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-19 | — | — | WO | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1180518-A1 | 5-PYRIDYL-1,3-AZOLE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | MAPK14 50/4885PTGS2 57/4885IKBKB 119/4885 |
| US-20060135566-A1 | 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof | ADORA3, MAPK4, MAPK3 | MAPK14 47/4885PTGS2 699/4885IKBKB 289/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | MAPK14 29/4885PTGS2 109/4885IKBKB 25/4885 |
| US-20090048307-A1 | 5-pyridyl-1, 3-azole compounds, process for producing the same and use there of | ADORA3, ADORA1, MAPK3 | MAPK14 73/4885PTGS2 728/4885IKBKB 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.